Otitopic, acquired by tobacco company Philip Morris International in 2021, was a dry powder inhalation company with expertise in formulation and drug delivery device development, including Asprihale®, a proprietary DPI aspirin formulation for cardiac indications.
Otitopic, acquired by tobacco company Philip Morris International in 2021, was a late-stage dry powder inhalation of aspirin company with a track record of success in pharmaceutical product drug delivery and drug device development. Asprihale® is a proprietary aspirin formulation administered via a DPI, entering the bloodstream faster than oral tablets, for cardiac indications.
Otitopic was pioneering a new class of dry-powder inhalation in the cardiovascular medicine field, based on its proprietary drug delivery platform.
Otitopic was founded in 2012.